Ligand Pharmaceuticals (LGND) Cash from Operations (2010 - 2026)

Ligand Pharmaceuticals has disclosed Cash from Operations across 17 years of filings, most recently posting 48691000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 48691000.0, up 291.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 123495000.0 (up 133.58% YoY), and the FY2025 annual result was 49359000.0, down 49.14% from the prior year.
• Cash from Operations came in at 48691000.0 for Q1 2026 at Ligand Pharmaceuticals, up from 45915000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 53472000.0 in Q4 2022 to a low of 25445000.0 in Q1 2025.
• The 5-year median for Cash from Operations is 18732000.0 (2024), against an average of 22501411.76.
• Across the five-year window, Cash from Operations jumped 16336.59% in 2024 and slumped 235.84% in 2025, its largest moves.
• Ligand Pharmaceuticals' Cash from Operations stood at 53472000.0 in 2022, then slumped by 84.92% to 8065000.0 in 2023, then soared by 253.02% to 28471000.0 in 2024, then surged by 61.27% to 45915000.0 in 2025, then climbed by 6.05% to 48691000.0 in 2026.
• The last three Cash from Operations figures came in at 48691000.0 (Q1 2026), 45915000.0 (Q4 2025), and 13090000.0 (Q3 2025), per Business Quant data.